Clinical Trial: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: SCLC,Extensive Stage
Study Type: OBSERVATIONAL
Official Title: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance
Brief Summary:
To validate the predictive value of transcriptome-based molecular subtyping of extensive stage small cell lung cancer (SCLC) for the efficacy of programmed death-1(PD-1)/programmed death-ligand1(PD-L1) inhibitor in the first line setting; to explore the differences of immune microenvironment between different SCLC subtypes to reveal the mechanisms of immunotherapy resistance of SCLC
Read more